Durvalumab Injection 120 mg/2.4 mL: Benefits, Uses, Dosage & Side Effects

Durvalumab Injection 120 mg/2.4 mL is an immunotherapy medicine containing durvalumab, a PD-L1 immune checkpoint inhibitor. It helps the immune system recognize and attack certain cancer cells. It is used for specific cancer indications based on local regulatory approvals in the USA, UK, UAE and South Africa.

What Is Durvalumab 120 mg/2.4 mL?

Durvalumab is a monoclonal antibody that blocks the PD-L1 pathway, helping immune cells maintain their ability to fight cancer. The 120 mg/2.4 mL presentation contains 120 mg of durvalumab in 2.4 mL and is administered by intravenous infusion.

Benefits of Durvalumab

Potential benefits when used for an approved indication include:

Helps the immune system fight cancer cells

Provides targeted immunotherapy

Used in selected lung cancer treatment plans

May be combined with chemotherapy or other anticancer medicines

Can be used in different stages of cancer treatment depending on the indication

Uses of Durvalumab Injection

Depending on the approved indication, durvalumab may be used for:

Non-small cell lung cancer (NSCLC)

Small-cell lung cancer (SCLC)

Biliary tract cancer

Hepatocellular carcinoma

Endometrial cancer

Approved uses can vary between countries and patient populations.

Durvalumab Dosage & Administration

The dosage depends on the type of cancer, treatment regimen, body weight where applicable and other medicines being used. Durvalumab is administered through an intravenous infusion by a qualified healthcare professional.

Patients should not change the prescribed dose or treatment schedule without medical supervision.

Side Effects

Commonly reported side effects may include:

Fatigue

Cough

Diarrhea

Rash or itching

Nausea

Decreased appetite

Muscle or joint pain

Shortness of breath

Infusion-related reactions

Durvalumab can also cause immune-related reactions affecting the lungs, liver, intestines, kidneys, skin and endocrine organs. Serious or unusual symptoms should be reported to a healthcare professional immediately.

Durvalumab in USA, UK, UAE & Singapore

Durvalumab is a prescription oncology medicine. Availability, approved indications, prescribing requirements and import regulations may differ in the USA, UK, UAE and Singapore. Hospitals, oncology centers, pharmacies and distributors should follow applicable local regulations.

FAQs

What is Durvalumab 120 mg/2.4 mL used for?

It is an immunotherapy used for selected cancer indications, including certain lung cancers and other approved cancers.

Is Durvalumab chemotherapy?

No. Durvalumab is an immunotherapy, although it may be used together with chemotherapy in certain treatment protocols.

How is Durvalumab given?

It is administered by intravenous infusion by trained healthcare professionals.

How often is Durvalumab administered?

The treatment schedule depends on the cancer type and prescribed treatment regimen.

Can Durvalumab cause serious side effects?

Yes. Immune-mediated reactions can sometimes be serious. Medical monitoring is important during treatment.

Can Durvalumab be used during pregnancy?

Durvalumab may pose risks to an unborn baby. Pregnancy and breastfeeding should be discussed with the treating healthcare professional.

Who should prescribe Durvalumab?

Durvalumab should be prescribed and monitored by a qualified oncologist or other appropriate specialist.

Key Product Details

Product: Durvalumab Injection

Strength: 120 mg/2.4 mL

Active Ingredient: Durvalumab

Class: PD-L1 Immune Checkpoint Inhibitor

Route: Intravenous infusion

Use: Selected cancer indications

Medical Disclaimer: This page provides general educational information and does not replace professional medical advice. Durvalumab is a prescription medicine, and its dosage and use should be determined by a qualified healthcare professional.